Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Common Equity: 2017-2021

Historic Common Equity for Cogent Biosciences (COGT) over the last 4 years, with Sep 2021 value amounting to $197.2 million.

  • Cogent Biosciences' Common Equity rose 989.50% to $197.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $197.2 million, marking a year-over-year increase of 989.50%. This contributed to the annual value of $234.7 million for FY2020, which is 638.83% up from last year.
  • According to the latest figures from Q3 2021, Cogent Biosciences' Common Equity is $197.2 million, which was down 7.31% from $212.8 million recorded in Q2 2021.
  • Cogent Biosciences' Common Equity's 5-year high stood at $234.7 million during Q4 2020, with a 5-year trough of -$61.3 million in Q1 2018.
  • In the last 3 years, Cogent Biosciences' Common Equity had a median value of $39.8 million in 2019 and averaged $94.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 177.47% in 2020, then surged by 1,005.99% in 2021.
  • Over the past 5 years, Cogent Biosciences' Common Equity (Quarterly) stood at -$48.8 million in 2017, then soared by 223.31% to $60.2 million in 2018, then tumbled by 47.27% to $31.8 million in 2019, then soared by 638.83% to $234.7 million in 2020, then surged by 989.50% to $197.2 million in 2021.
  • Its Common Equity was $197.2 million in Q3 2021, compared to $212.8 million in Q2 2021 and $226.8 million in Q1 2021.